Friday, 22 Mar 2019

You are here

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage according to a study presented at the 2017 American Heart Association  (AHA) meeting and reported by Medscape.

A subanalysis of the 24,000 patients from the PRECISION trial was conducted to look at those who also took aspirin.

For those not taking aspirin, naproxen or ibuprofen had significantly greater risk of major adverse CV events (MACE), non-CV death, gastrointestinal (GI) events, and renal events than those receiving celecoxib.

The ibuprofen group also had significantly greater risk for MACE alone, for GI events, and for renal events vs the study-drug group; while the naproxen group had significantly greater risk for just GI and renal events.

The subanalyses shows that for those who take aspirin, the risk for the composite end point and for renal events was significantly greater only for the ibuprofen group; the risk for GI events was still greater for both groups vs those receiving celecoxib; and there were no longer any significant between-group differences in risk for MACE alone.

The presenting authors suggest that "you shouldn't take aspirin if you dont need aspirin".

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRA Position Statement on Medical Cannabis Use

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.

Senate Drills Drug Makers Over Price

Reuters reported that today, the US Senate Finance Committee met to question the executives from seven US pharmaceutical companies on the rising price drugs in America. 

Canadian Vaccination Guidelines for the Immunosuppressed

A multidisciplinary Canadian task force has developed guidelines for vaccination in patients receiving immunosuppressive therapies, based on the evidence that immunosuppressive use in immune-mediated disease may be  associated with an elevated risk of infections. 

No Difference in Oral or IV Antibiotics for Bone & Joint Infections

Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.

There is considerable discussion whether complex bone and joint infections must be managed with prolonged intravenous antibiotics or if oral antibiotic therapy may suffice. 

2019: the Year of Price Hikes

In 2019 there have been numerous reports of higher drug pricing for many drugs.  Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.

Reuters reports that in the United States, the pricing on more than 250 prescription drugs have gone up.